Abstract:Sporadic amyotrophic lateral sclerosis (ALS) is a fatal adult-onset neurodegenerative disease with unknown causes and few treatment options. Here we report the first multi-dimensional single-cell landscape of the peripheral blood mononuclear cell samples from seven ALS patients representing three distinct disease stages: Early, Mid and Late. Our multipronged analyses revealed the over-activation of immune cells especially in the Mid and Late ALS stages, which is characterized by the increased cytotoxic CD8+ effector cells, expanded TCR clonotypes, upregulated oxidative phosphorylation and ribosomal genes across many cell types. More importantly, the current study discovered novel genes strongly correlated with ALS conditions, such as FOXO1 and TGFBR2 responsible for the aberrant T cell activation, and XBP1 and SPIB accountable for excessive oxidative stress. We further identified 60 genes that distinguished ALS patients from healthy donors with an unprecedented accuracy of 93% against an independent cohort of 792 specimens. Our findings provide new molecular and cellular insights into the mechanisms of ALS onset and progression, and offer novel strategies for accurate diagnosis and potential therapeutic development. ### Competing Interest Statement Q.W. is an employee of Harcam Biomedicines who is bound by confidentiality agreements that prevents her from disclosing the competing interests in this work. All remaining authors declare no competing interest. ### Funding Statement This work was partially supported by Major Special Program Grant of Shanghai Municipality (Award Number 2017SHZDZX01), National Key Research and Development Program of China (Award Number 2021YFF1200400) and Shanghai Municipal Science and Technology Major Project (Award Number 2018SHZDZX01). ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: This study was approved by the Ethics Committee of the Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine (Approval #2020-060-02). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable. Yes All data produced in the present study are available upon reasonable request to the authors

Genome-wide DNA methylation analysis related to ALS patient progression and survival

Epigenome-wide DNA methylation study of whole blood in patients with sporadic amyotrophic lateral sclerosis

Clinical and genetic characteristics of ALS patients with variants in genes regulating DNA methylation

Genome-wide study of DNA methylation in Amyotrophic Lateral Sclerosis identifies differentially methylated loci and implicates metabolic, inflammatory and cholesterol pathways

Genome-Wide Methylation Profiling of lncRNAs Reveals a Novel Progression-Related and Prognostic Marker for Colorectal Cancer

Sex-specific DNA methylation differences in Amyotrophic lateral sclerosis

Genome-wide study of DNA methylation shows alterations in metabolic, inflammatory, and cholesterol pathways in ALS

Mitochondrial D-loop methylation levels inversely correlate with disease duration in amyotrophic lateral sclerosis

DNA methylome, R-loop and clinical exome profiling of patients with sporadic amyotrophic lateral sclerosis

Tissue informative cell-free DNA methylation sites in amyotrophic lateral sclerosis

Aberrant DNA and RNA Methylation Occur in Spinal Cord and Skeletal Muscle of Human SOD1 Mouse Models of ALS and in Human ALS: Targeting DNA Methylation Is Therapeutic

Methylation of Α-Synuclein and Leucine-Rich Repeat Kinase 2 in Leukocyte DNA of Parkinson's Disease Patients

A Genome-wide Expression Association Analysis Identifies Genes and Pathways Associated with Amyotrophic Lateral Sclerosis

Epigenetic age acceleration is associated with occupational exposures, sex, and survival in amyotrophic lateral sclerosis

Evidence for the potential role of m6A modification in regulating autophagy in models of amyotrophic lateral sclerosis

Epigenome-wide DNA methylation analysis of late-stage mild cognitive impairment

DNA Methylation Analysis Identifies Patterns in Progressive Glioma Grades to Predict Patient Survival

Identification Of Dna Methylation Prognostic Signature Of Acute Myelocytic Leukemia

Distinct CSF biomarker-associated DNA methylation in Alzheimer's disease and cognitively normal subjects

Single-cell transcriptional landscape of peripheral immunity and biomarkers for human sporadic amyotrophic lateral sclerosis patients

Dysregulated N6-methyladenosine modification in peripheral immune cells contributes to the pathogenesis of amyotrophic lateral sclerosis